Vaccine adjuvants as stand-alone immunoprophylaxis in strategies for 100-day rapid responses to future pandemics.

The COVID-19 pandemic accelerated vaccinology progress, driving rapid vaccine development for infectious and non-infectious diseases. However, challenges persist: malaria, HIV, and dengue lack fully effective vaccines, whereas influenza and tuberculosis face waning efficacy. Emerging pathogens and drug-resistant strains further highlight the need for improved vaccines, particularly those offering rapid deployment, broad immunogenicity, and durable protection against variants. Adjuvants can play a dual role in this context: as new stand-alone tools for an early response to a pandemic -aiming at the 100-days mission objective- and for prevention of anti-microbial resistance (AMR); and as traditional components enhancing the efficacy and breadth of vaccines. The understanding of their mechanisms of action and novel usage could address critical gaps in pandemic preparedness, especially for vulnerable populations like children and the elderly.

• Publication year

  2025

• Venue

  International Immunology

• Publication date

  2025-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/intimm/dxaf053PMID 40884464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• STING agonist-based ER-targeting molecules boost antigen cross-presentation

  2025cited by this paper
• Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization

  2025cited by this paper
• An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics.

  2025cited by this paper
• Antiviral activity of tecovirimat against monkeypox virus clades 1a, 1b, 2a, and 2b.

  2025cited by this paper
• A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.

  2025cited by this paper
• MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

  2024cited by this paper
• A Narrative Review on the Pandemic Zoonotic RNA Virus Infections Occurred During the Last 25 Years

  2024cited by this paper
• mRNA vaccines for infectious diseases — advances, challenges and opportunities

  2024cited by this paper
• Africa aims to avert an mpox pandemic

  2024cited by this paper
• Optimising vaccine immunogenicity in ageing populations: key strategies.

  2024cited by this paper
• Transforming vaccinology.

  2024cited by this paper
• Precision adjuvants for pediatric vaccines

  2024cited by this paper
• Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates.

  2024cited by this paper
• The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis

  2024cited by this paper
• Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1

  2024cited by this paper
• Deciphering Host–Parasite Interplay in Leishmania Infection through a One Health View of Proteomics Studies on Drug Resistance

  2024cited by this paper
• Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine

  2024cited by this paper
• Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity

  2024cited by this paper
• Highly pathogenic H5N1 avian influenza virus outbreak in cattle: the knowns and unknowns

  2024cited by this paper
• Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.

  2024cited by this paper
• Pandemic preparedness through vaccine development for avian influenza viruses

  2024cited by this paper
• The scope of the antimicrobial resistance challenge.

  2024cited by this paper
• SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.

  2024cited by this paper
• Combating antimicrobial resistance in malaria, HIV and tuberculosis

  2024cited by this paper
• Effect of human H3N2 influenza virus reassortment on influenza incidence and severity during the 2017–18 influenza season in the USA: a retrospective observational genomic analysis

  2024cited by this paper
• CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age

  2024cited by this paper
• Vaccine adjuvants: Tailoring innate recognition to send the right message.

  2024cited by this paper
• Physiological functions of RIG-I-like receptors.

  2024cited by this paper
• Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

  2024cited by this paper
• AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans

  2024cited by this paper
• The emergence of artemisinin partial resistance in Africa: how do we respond?

  2024cited by this paper
• Fighting flu: novel CD8+ T‐cell targets are required for future influenza vaccines

  2024cited by this paper
• A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease.

  2024cited by this paper
• Vaccine Strategies to Elicit Mucosal Immunity

  2024cited by this paper
• Malaria vaccines for children: and now there are two.

  2024cited by this paper
• Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2

  2024cited by this paper
• Development and use of machine learning algorithms in vaccine target selection

  2024cited by this paper
• Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation

  2024cited by this paper
• Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers

  2024cited by this paper
• The protozoan commensal Tritrichomonas musculis is a natural adjuvant for mucosal IgA

  2024cited by this paper
• The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.

  2023cited by this paper
• The rapid emergence of antifungal-resistant human-pathogenic fungi

  2023cited by this paper
• Potential Causes of Spread of Antimicrobial Resistance and Preventive Measures in One Health Perspective-A Review

  2023cited by this paper
• The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains

  2023cited by this paper
• Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines

  2023cited by this paper
• Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States.

  2023cited by this paper
• The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century

  2023cited by this paper
• Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

  2023cited by this paper
• Which Virus Will Cause the Next Pandemic?

  2023cited by this paper
• BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance

  2023cited by this paper
• Outlook of pandemic preparedness in a post-COVID-19 world

  2023cited by this paper
• A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens

  2023cited by this paper
• 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation

  2023cited by this paper
• Resolving adjuvant mode of action to enhance vaccine efficacy.

  2022cited by this paper
• An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives

  2022cited by this paper
• Making innate sense of mRNA vaccine adjuvanticity

  2022cited by this paper
• Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

  2022cited by this paper
• Delivering Pandemic Vaccines in 100 Days - What Will It Take?

  2022cited by this paper
• BCG vaccination provides protection against IAV but not SARS-CoV-2

  2022cited by this paper
• Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

  2022cited by this paper
• The overlooked pandemic of antimicrobial resistance

  2022cited by this paper
• The Vaccine-Hesitant Moment

  2022cited by this paper
• Nasal vaccines: solutions for respiratory infectious diseases.

  2022cited by this paper
• Vaccine adjuvants to engage the cross-presentation pathway

  2022cited by this paper
• Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness

  2022cited by this paper
• Bioinspired vaccines to enhance MHC class-I antigen cross-presentation.

  2022cited by this paper
• Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

  2021cited by this paper
• Global, regional, and national causes of under-5 mortality in 2000–19: an updated systematic analysis with implications for the Sustainable Development Goals

  2021cited by this paper
• Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure.

  2021cited by this paper
• COVID-19 vaccine platforms: Delivering on a promise?

  2021cited by this paper
• HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens

  2021cited by this paper
• The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.

  2021cited by this paper
• Mucosal vaccines — fortifying the frontiers

  2021cited by this paper
• Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

  2021cited by this paper
• Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults

  2021cited by this paper
• Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants

  2021cited by this paper
• Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

  2021cited by this paper
• Pharmacological activation of STING blocks SARS-CoV-2 infection

  2021cited by this paper
• Emerging concepts in the science of vaccine adjuvants

  2021cited by this paper
• Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction

  2021cited by this paper
• Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

  2020cited by this paper
• Cross-presentation of exogenous antigens on MHC I molecules.

  2020cited by this paper
• Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal

  2020cited by this paper
• Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults

  2020cited by this paper
• IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination

  2020cited by this paper
• Did the hesitancy in declaring COVID-19 a pandemic reflect a need to redefine the term?

  2020cited by this paper
• Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation.

  2020cited by this paper
• Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway

  2020cited by this paper
• The Impact of the Microbiome on Immunity to Vaccination in Humans

  2020cited by this paper
• The host targeting effect of chloroquine in malaria

  2020cited by this paper
• First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).

  2020cited by this paper
• Why and How Vaccines Work

  2020cited by this paper
• A guide to vaccinology: from basic principles to new developments

  2020cited by this paper
• The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.

  2019cited by this paper
• Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.

  2019cited by this paper
• Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types

  2019cited by this paper
• Human CD8+ T cell cross-reactivity across influenza A, B and C viruses

  2019cited by this paper
• Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses

  2019cited by this paper
• β-Glucan-Induced Trained Immunity Protects against Leishmania braziliensis Infection: a Crucial Role for IL-32.

  2019cited by this paper
• MAIT cells as attractive vaccine targets

  2019cited by this paper

• No citing papers are available for this paper.